Bone morphogenetic protein

Bone Morphogenetic Protein
By: Kim Stephens
http://www.ele.uri.edu/

Bone Morphogenetic Proteins
Eric Niederhoffer, SIU-SOM
http://www.siumed.edu/

The TGFß Superfamily - A Tale of Gene Duplication and Divergence
Billie J. Swalla
http://courses.washington.edu/

Biological Treatment for Periodontal Regeneration
http://www.dent.ohio-state.edu

Adaptive Radiations & Development
http://www.bio.georgiasouthern.edu/

Vascular Calcification
Kristina Boström, MD, PhD
http://www.mcdb.ucla.edu

Introduction to Biological Sequences
http://web.cecs.pdx.edu

“Delivery of Insulin-Like Growth Factor-I to the Rat Brain and Spinal cord along Olfactory and Trigeminal Pathways Following Intranasal Administration.”
Thorne, R. G., Pronk, G. J., Padmanabhan, V., and Frey II, W. H.
http://www.igert.neu.edu/

Mutants  genetic variation in human development
http://faculty.bennington.edu

LT-Cage INFUSE Bone Graft for Vertebral Fusion
Ramandeep Mehmi
http://www.sjsu.edu/

BMP receptor1A
Jena Buchan
http://courses.bio.unc.edu/

Collagen Degradation
https://medschool.mc.vanderbilt.edu


404 Published articles free access to full text

1. spinal neuron differentiation.
2. Novel analysis model for implant osseointegration using ectopic bone formation via the recombinant human bone morphogenetic protein-2/macroporous biphasic calcium phosphate block system in rats: a proof-of-concept study.
3. Improvement of osteogenic potential of biphasic calcium phosphate bone substitute coated with two concentrations of expressed recombinant human bone morphogenetic protein 2.
4. Structure of the Bone Morphogenetic Protein Receptor ALK2 and Implications for Fibrodysplasia Ossificans Progressiva.
5. Zoledronate inhibits phosphate and bone morphogenetic protein 2-induced extracellular calcification of vascular smooth muscle cells in vitro.
6. Activation of the canonical Bone Morphogenetic Protein (BMP) pathway during lung morphogenesis and adult lung tissue repair.
7. The hedgehog signal induced modulation of bone morphogenetic protein signaling: an essential signaling relay for urinary tract morphogenesis.
8. Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming.
9. DSP-PP precursor protein cleavage by tolloid-related-1 protein and by bone morphogenetic protein-1.
10. Multistep molecular mechanism for bone morphogenetic protein extracellular transport in the Drosophila embryo.
11. The bone morphogenetic protein receptor-1A pathway is required for lactogenic differentiation of mammary epithelial cells in vitro.
12. Eps15R is required for bone morphogenetic protein signalling and differentially compartmentalizes with Smad proteins.
13. A crucial role of bone morphogenetic protein signaling in the wound healing response in acute liver injury induced by carbon tetrachloride.
14. Overexpression of bone morphogenetic protein 4 in STO fibroblast feeder cells represses the proliferation of mouse embryonic stem cells in vitro.
15. The use of recombinant human bone morphogenetic protein-2 for the treatment of a delayed union following femoral neck open-wedge osteotomy.
16. Repetitive recombinant human bone morphogenetic protein 2 injections improve the callus microarchitecture and mechanical stiffness in a sheep model of distraction osteogenesis.
17. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells.
18. Bone morphogenetic protein-2-induced Wnt/β-catenin signaling pathway activation through enhanced low-density-lipoprotein receptor-related protein 5 catabolic activity contributes to hypertrophy in osteoarthritic chondrocytes.
19. Possible Involvement of Smad Signaling Pathways in Induction of Odontoblastic Properties in KN-3 Cells by Bone Morphogenetic Protein-2: A Growth Factor to Induce Dentin Regeneration.
20. Induction of superficial zone protein (SZP)/lubricin/PRG 4 in muscle-derived mesenchymal stem/progenitor cells by transforming growth factor-β1 and bone morphogenetic protein-7.
21. Effect of bone morphogenetic protein-2 on proliferation and apoptosis of gastric cancer cells.
22. Size control of the Drosophila hematopoietic niche by bone morphogenetic protein signaling reveals parallels with mammals.
23. Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration.
24. Different requirements for proteolytic processing of bone morphogenetic protein 5/6/7/8 ligands in Drosophila melanogaster.
25. The effect of platelet rich plasma from bone marrow aspirate with added bone morphogenetic protein-2 on the Achilles tendon-bone junction in rabbits.
26. Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia.
27. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone.
28. Response of osteoblast-like cells cultured on zirconia to bone morphogenetic protein-2.
29. Inductive specification and axonal orientation of spinal neurons mediated by divergent bone morphogenetic protein signaling pathways.
30. Improved spinal fusion efficacy by long-term delivery of bone morphogenetic protein-2 in a rabbit model.
31. Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.
32. Lack of association of bone morphogenetic protein 2 gene haplotypes with bone mineral density, bone loss, or risk of fractures in men.
33. Bone morphogenetic protein-2 activates NADPH oxidase to increase endoplasmic reticulum stress and human coronary artery smooth muscle cell calcification.
34. Tbx20 transcription factor is a downstream mediator for bone morphogenetic protein-10 in regulating cardiac ventricular wall development and function.
35. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.
36. Myo/Nog cell regulation of bone morphogenetic protein signaling in the blastocyst is essential for normal morphogenesis and striated muscle lineage specification.
37. Bone morphogenetic protein inhibition promotes neurological recovery after intraventricular hemorrhage.
38. Functional restoration of critically sized segmental defects with bone morphogenetic protein-2 and heparin treatment.
39. Bone morphogenetic protein receptor II is a novel mediator of endothelial nitric-oxide synthase activation.
40. Mutation in the type IB bone morphogenetic protein receptor Alk6b impairs germ-cell differentiation and causes germ-cell tumors in zebrafish.
41. Biodegradable composite scaffolds incorporating an intramedullary rod and delivering bone morphogenetic protein-2 for stabilization and bone regeneration in segmental long bone defects.
42. Bone morphogenetic protein endothelial cell precursor-derived regulator regulates retinal angiogenesis in vivo in a mouse model of oxygen-induced retinopathy.
43. Bone morphogenetic protein-2 functions as a negative regulator in the differentiation of myoblasts, but not as an inducer for the formations of cartilage and bone in mouse embryonic tongue.
44. Bone morphogenetic protein-3b (BMP-3b) is expressed in adipocytes and inhibits adipogenesis as a unique complex.
45. Recombinant human bone morphogenetic protein 2 labeled use in spinal surgery and sexual dysfunction.
46. Bone morphogenetic protein-1 processes insulin-like growth factor-binding protein 3.
47. down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4.
48. Negative feedback in the bone morphogenetic protein 4 (BMP4) synexpression group governs its dynamic signaling range and canalizes development.
49. Bone morphogenetic protein 3 controls insulin gene expression and is down-regulated in INS-1 cells inducibly expressing a hepatocyte nuclear factor 1A-maturity-onset diabetes of the young mutation.
50. Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects.
51. Differentiation of an embryonic stem cell to hemogenic endothelium by defined factors: essential role of bone morphogenetic protein 4.
52. Nuclear factor-kappaB (NF-kappaB) p65 interacts with Stat5b in growth plate chondrocytes and mediates the effects of growth hormone on chondrogenesis and on the expression of insulin-like growth factor-1 and bone morphogenetic protein-2.
53. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.
54. Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling.
55. Use of recombinant human bone morphogenetic protein-2 as an adjunct for instrumented posterior arthrodesis in the occipital cervical region: An analysis of safety, efficacy, and dosing.
56. Furin is the major processing enzyme of the cardiac-specific growth factor bone morphogenetic protein 10.
57. Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2.
58. Regeneration of axons in injured spinal cord by activation of bone morphogenetic protein/Smad1 signaling pathway in adult neurons.
59. An in vivo map of bone morphogenetic protein 2 post-transcriptional repression in the heart.
60. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice.
61. Follistatin-like 1 (Fstl1) is a bone morphogenetic protein (BMP) 4 signaling antagonist in controlling mouse lung development.
62. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy.
63. Formation of stable homomeric and transient heteromeric bone morphogenetic protein (BMP) receptor complexes regulates Smad protein signaling.
64. Notch signaling pathway enhances bone morphogenetic protein 2 (BMP2) responsiveness of Msx2 gene to induce osteogenic differentiation and mineralization of vascular smooth muscle cells.
65. Reconstruction of the alveolar cleft: can growth factor-aided tissue engineering replace autologous bone grafting? A literature review and systematic review of results obtained with bone morphogenetic protein-2.
66. Commentary on an article by Hannu T. Aro, MD, PhD, et al.: "Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation".
67. Novel contact-dependent bone morphogenetic protein (BMP) signaling mediated by heparan sulfate proteoglycans.
68. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis.
69. Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration.
70. Quantitative analysis of bone morphogenetic protein 15 (BMP15) and growth differentiation factor 9 (GDF9) gene expression in calf and adult bovine ovaries.
71. Bone morphogenetic protein signaling is required in the dorsal neural folds before neurulation for the induction of spinal neural crest cells and dorsal neurons.
72. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.
73. Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas.
74. Sustained release of bone morphogenetic protein-4 in adult rabbit extraocular muscle results in decreased force and muscle size: potential for strabismus treatment.
75. Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis.
76. Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy.
77. Regeneration of bone- and tendon/ligament-like tissues induced by gene transfer of bone morphogenetic protein-12 in a rat bone defect.
78. Bone morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the BMP antagonist, twisted gastrulation.
79. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4.
80. Genetic and evolutionary analyses of the human bone morphogenetic protein receptor 2 (BMPR2) in the pathophysiology of obesity.
81. The bone morphogenetic protein antagonist noggin protects white matter after perinatal hypoxia-ischemia.
82. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo.
83. Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway.
84. Osseointegration by bone morphogenetic protein-2 and transforming growth factor beta2 coated titanium implants in femora of New Zealand white rabbits.
85. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus.
86. Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells.
87. The amiloride derivative phenamil attenuates pulmonary vascular remodeling by activating NFAT and the bone morphogenetic protein signaling pathway.
88. A synthetic compound that potentiates bone morphogenetic protein-2-induced transdifferentiation of myoblasts into the osteoblastic phenotype.
89. The bone morphogenetic protein roof plate chemorepellent regulates the rate of commissural axonal growth.
90. Bone morphogenetic protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis.
91. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling.
92. Lissencephaly-1 controls germline stem cell self-renewal through modulating bone morphogenetic protein signaling and niche adhesion.
93. Delivery of plasmid DNA encoding bone morphogenetic protein-2 with a biodegradable branched polycationic polymer in a critical-size rat cranial defect model.
94. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways.
95. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro.
96. The suppression of CRMP2 expression by bone morphogenetic protein (BMP)-SMAD gradient signaling controls multiple stages of neuronal development.
97. Induction of interleukin-6 expression by bone morphogenetic protein-6 in macrophages requires both SMAD and p38 signaling pathways.
98. Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II.
99. TRE17/ubiquitin-specific protease 6 (USP6) oncogene translocated in aneurysmal bone cyst blocks osteoblastic maturation via an autocrine mechanism involving bone morphogenetic protein dysregulation.
100. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor hetero-oligomerization.
101. Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2+]i in rat distal pulmonary arterial smooth muscle cells.
102. WASP is activated by phosphatidylinositol-4,5-bisphosphate to restrict synapse growth in a pathway parallel to bone morphogenetic protein signaling.
103. Bone morphogenetic protein signaling regulates gastric epithelial cell development and proliferation in mice.
104. Insulin-like growth factor 1 synergizes with bone morphogenetic protein 7-mediated anabolism in bovine intervertebral disc cells.
105. Bone morphogenetic protein-7 promotes chondrogenesis in human amniotic epithelial cells.
106. Bone morphogenetic protein signaling: implications in urology.
107. Does bone morphogenetic protein 6 (BMP6) affect female fertility in the mouse?
108. Casein kinase 2 beta-subunit is a regulator of bone morphogenetic protein 2 signaling.
109. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.
110. WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)/Smad/Id1 signaling.
111. Enhanced bone morphogenetic protein-2-induced ectopic and orthotopic bone formation by intermittent parathyroid hormone (1-34) administration.
112. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7.
113. Bone morphogenetic protein receptor in the osteogenic differentiation of rat bone marrow stromal cells.
114. Transforming growth factor β, bone morphogenetic protein, and vascular endothelial growth factor mediate phenotype maturation and tissue remodeling by embryonic valve progenitor cells: relevance for heart valve tissue engineering.
115. Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.
116. Cross talk between insulin and bone morphogenetic protein signaling systems in brown adipogenesis.
117. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF).
118. Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells.
119. A new technique for seeding chondrocytes onto solvent-preserved human meniscus using the chemokinetic effect of recombinant human bone morphogenetic protein-2.
120. BMP9 (bone morphogenetic protein 9) induces NGF as an autocrine/paracrine cholinergic trophic factor in developing basal forebrain neurons.
121. ZFP423 coordinates Notch and bone morphogenetic protein signaling, selectively up-regulating Hes5 gene expression.
122. Soluble repulsive guidance molecule c/hemojuvelin is a broad spectrum bone morphogenetic protein (BMP) antagonist and inhibits both BMP2- and BMP6-mediated signaling and gene expression.
123. Mesenchymal bone morphogenetic protein signaling is required for normal pancreas development.
124. Caenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signaling.
125. Bone morphogenetic protein 4 mediates human embryonic germ cell derivation.
126. Bone morphogenetic protein-2 and -6 heterodimer illustrates the nature of ligand-receptor assembly.
127. Management of subtrochanteric femur fractures with internal fixation and recombinant human bone morphogenetic protein-7 in a patient with osteopetrosis: a case report.
128. Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor beta- and bone morphogenetic protein-independent manner.
129. Controlled spatial and conformational display of immobilised bone morphogenetic protein-2 and osteopontin signalling motifs regulates osteoblast adhesion and differentiation in vitro.
130. Bone morphogenetic protein signaling in the developing telencephalon controls formation of the hippocampal dentate gyrus and modifies fear-related behavior.
131. MicroRNA miR-155 inhibits bone morphogenetic protein (BMP) signaling and BMP-mediated Epstein-Barr virus reactivation.
132. Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13.
133. Stromal derived factor-1 regulates bone morphogenetic protein 2-induced osteogenic differentiation of primary mesenchymal stem cells.
134. First evidence of bone morphogenetic protein 1 expression and activity in sheep ovarian follicles.
135. Bone morphogenetic protein 2 stimulates endochondral ossification by regulating periosteal cell fate during bone repair.
136. Distinct functionalities of bone morphogenetic protein antagonists during fracture healing in mice.
137. Microtubule stabilization by bone morphogenetic protein receptor-mediated scaffolding of c-Jun N-terminal kinase promotes dendrite formation.
138. Enhanced bone formation in large segmental radial defects by combining adipose-derived stem cells expressing bone morphogenetic protein 2 with nHA/RHLC/PLA scaffold.
139. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.
140. The effect of NELL1 and bone morphogenetic protein-2 on calvarial bone regeneration.
141. Roles of bone morphogenetic protein signaling and its antagonism in holoprosencephaly.
142. Bone morphogenetic protein-7 inhibits proximal tubular epithelial cell Smad3 signaling via increased SnoN expression.
143. Dentin sialophosphoprotein (DSPP) is cleaved into its two natural dentin matrix products by three isoforms of bone morphogenetic protein-1 (BMP1).
144. Golgi apparatus casein kinase phosphorylates bioactive Ser-6 of bone morphogenetic protein 15 and growth and differentiation factor 9.
145. Nitric oxide modulates recombinant human bone morphogenetic protein-2-induced corticocancellous autograft incorporation: a study in rat intertransverse fusion.
146. Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity.
147. Effects of polycaprolactone-tricalcium phosphate, recombinant human bone morphogenetic protein-2 and dog mesenchymal stem cells on bone formation: pilot study in dogs.
148. Differentiation of embryonic stem cells 1 (Dies1) is a component of bone morphogenetic protein 4 (BMP4) signaling pathway required for proper differentiation of mouse embryonic stem cells.
149. Inkjet-based biopatterning of bone morphogenetic protein-2 to spatially control calvarial bone formation.
150. Decorin is processed by three isoforms of bone morphogenetic protein-1 (BMP1).
151. Transcriptional control of human antigen R by bone morphogenetic protein.
152. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation.
153. Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation.
154. Control of the bone morphogenetic protein 7 gene in developmental and adult life.
155. Nephroblastoma overexpressed (Nov) inactivation sensitizes osteoblasts to bone morphogenetic protein-2, but nov is dispensable for skeletal homeostasis.
156. Recombinant human bone morphogenetic protein-7 enhances fracture healing in an ischemic environment.
157. Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial hypertension.
158. Development and optimization of a cell-based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein-2 activity.
159. Osteogenic differentiation of human amniotic fluid-derived stem cells induced by bone morphogenetic protein-7 and enhanced by nanofibrous scaffolds.
160. The extracellular regulation of bone morphogenetic protein signaling.
161. Tumor necrosis factor alpha represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-kappaB.
162. Bone morphogenetic protein-6 promotes cerebellar granule neurons survival by activation of the MEK/ERK/CREB pathway.
163. Phosphatidylinositol 3 kinase/Akt signal relay cooperates with smad in bone morphogenetic protein-2-induced colony stimulating factor-1 (CSF-1) expression and osteoclast differentiation.
164. Retinoic acid enhances skeletal muscle progenitor formation and bypasses inhibition by bone morphogenetic protein 4 but not dominant negative beta-catenin.
165. The spatial patterning of mouse cone opsin expression is regulated by bone morphogenetic protein signaling through downstream effector COUP-TF nuclear receptors.
166. Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells.
167. Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer.
168. Bone morphogenetic protein-6 induces the expression of inducible nitric oxide synthase in macrophages.
169. Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors.
170. Vascular endothelial growth factor inhibits bone morphogenetic protein 2 expression in rat mesenchymal stem cells.
171. Bone morphogenetic protein 2 enhances PGE(2)-stimulated osteoclast formation in murine bone marrow cultures.
172. The classic: Bone morphogenetic protein.
173. p63 Suppresses non-epidermal lineage markers in a bone morphogenetic protein-dependent manner via repression of Smad7.
174. S100A4 and bone morphogenetic protein-2 codependently induce vascular smooth muscle cell migration via phospho-extracellular signal-regulated kinase and chloride intracellular channel 4.
175. Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures.
176. Bone morphogenetic protein antagonist noggin promotes skin tumorigenesis via stimulation of the Wnt and Shh signaling pathways.
177. Release characteristics and osteogenic activity of recombinant human bone morphogenetic protein-2 grafted to novel self-assembled poly(lactide-co-glycolide fumarate) nanoparticles.
178. Heat shock protein 70 enhances vascular bone morphogenetic protein-4 signaling by binding matrix Gla protein.
179. Stable expression and characterization of N-terminal tagged recombinant human bone morphogenetic protein 15.
180. Epicardium and myocardium separate from a common precursor pool by crosstalk between bone morphogenetic protein- and fibroblast growth factor-signaling pathways.
181. Expression of bone morphogenetic protein-2 in the chondrogenic and ossifying sites of calcific tendinopathy and traumatic tendon injury rat models.
182. Fibronectin binds and enhances the activity of bone morphogenetic protein 1.
183. Molecular regulation of matrix extracellular phosphoglycoprotein expression by bone morphogenetic protein-2.
184. Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis.
185. Bone morphogenetic protein 15 (BMP15) acts as a BMP and Wnt inhibitor during early embryogenesis.
186. Repair of experimentally induced large osteochondral defects in rabbit knee with various concentrations of Escherichia coli-derived recombinant human bone morphogenetic protein-2.
187. Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity.
188. The bone morphogenetic protein signaling pathway is upregulated in a mouse model of total parenteral nutrition.
189. MicroRNA-141 and -200a are involved in bone morphogenetic protein-2-induced mouse pre-osteoblast differentiation by targeting distal-less homeobox 5.
190. Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes.
191. Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection.
192. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study.
193. Role of dimerization and substrate exclusion in the regulation of bone morphogenetic protein-1 and mammalian tolloid.
194. Xenopus SMOC-1 Inhibits bone morphogenetic protein signaling downstream of receptor binding and is essential for postgastrulation development in Xenopus.
195. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis.
196. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
197. New insights into bone morphogenetic protein signaling: focus on angiogenesis.
198. Multiple signaling pathways converge to regulate bone-morphogenetic-protein-dependent glial gene expression.
199. Bone morphogenetic protein 4 stimulates neuronal differentiation of neuronal stem cells through the ERK pathway.
200. Reovirus activates transforming growth factor beta and bone morphogenetic protein signaling pathways in the central nervous system that contribute to neuronal survival following infection.
201. Dose effect of dual delivery of vascular endothelial growth factor and bone morphogenetic protein-2 on bone regeneration in a rat critical-size defect model.
202. Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.
203. ANA deficiency enhances bone morphogenetic protein-induced ectopic bone formation via transcriptional events.
204. The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation.
205. Bone morphogenetic protein 2 signals via BMPR1A to regulate murine follicle-stimulating hormone beta subunit transcription.
206. Effect of bone morphogenetic protein-6 on macrophages.
207. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways.
208. Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification.
209. Inhibition of microtubule assembly in osteoblasts stimulates bone morphogenetic protein 2 expression and bone formation through transcription factor Gli2.
210. Bone morphogenetic protein-2: a potential regulator in scleral remodeling.
211. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
212. Expression of bone morphogenetic protein receptor (BMPR) during perinatal ovary development and primordial follicle formation in the hamster: possible regulation by FSH.
213. Mitogen limitation and bone morphogenetic protein-4 promote neurogenesis in SFME cells, an EGF-dependent neural stem cell line.
214. A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7.
215. Improved bone healing by angiogenic factor-enriched platelet-rich plasma and its synergistic enhancement by bone morphogenetic protein-2.
216. Effect of bone morphogenetic protein signaling on development of the jaw skeleton.
217. Influence of bone morphogenetic protein-2 on the extracellular matrix, material properties, and gene expression of long-term articular chondrocyte cultures: loss of chondrocyte stability.
218. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
219. Effect of autologous bone marrow stromal cell seeding and bone morphogenetic protein-2 delivery on ectopic bone formation in a microsphere/poly(propylene fumarate) composite.
220. Conversion of the nipple to hair-bearing epithelia by lowering bone morphogenetic protein pathway activity at the dermal-epidermal interface.
221. Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression.
222. Dynamic activation of bone morphogenetic protein signaling in collagen-induced arthritis supports their role in joint homeostasis and disease.
223. 9-Cis-retinoic acid reduces ischemic brain injury in rodents via bone morphogenetic protein.
224. Influences of reduced expression of maternal bone morphogenetic protein 2 on mouse embryonic development.
225. A bone morphogenetic protein homologue in the parasitic flatworm, Schistosoma mansoni.
226. Alendronate inhibits PTH (1-34)-induced bone morphogenetic protein expression in MC3T3-E1 preosteoblastic cells.
227. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure.
228. Suppression of bone morphogenetic protein inhibitors promotes osteogenic differentiation: therapeutic implications.
229. Species-specific cis-regulatory elements in the 3'-untranslated region direct alternative polyadenylation of bone morphogenetic protein 2 mRNA.
230. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
231. SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis.
232. Crossveinless-2 controls bone morphogenetic protein signaling during early cardiomyocyte differentiation in P19 cells.
233. Bone morphogenetic protein 4 signaling regulates development of the anterior visceral endoderm in the mouse embryo.
234. Nigrostriatal alterations in bone morphogenetic protein receptor II dominant negative mice.
235. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.
236. Variation in bone morphogenetic protein 15 is not associated with spontaneous human dizygotic twinning.
237. Chordin-like 1, a bone morphogenetic protein-4 antagonist, is upregulated by hypoxia in human retinal pericytes and plays a role in regulating angiogenesis.
238. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study.
239. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells.
240. Bone morphogenetic protein regulation of enteric neuronal phenotypic diversity: relationship to timing of cell cycle exit.
241. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2.
242. Bone morphogenetic protein 2 mediates dentin sialophosphoprotein expression and odontoblast differentiation via NF-Y signaling.
243. Bone morphogenetic protein signalling is required for the anti-mitogenic effect of the proteasome inhibitor MG-132 on colon cancer cells.
244. Crystallization and preliminary X-ray analysis of the complex of the first von Willebrand type C domain bound to bone morphogenetic protein 2.
245. Association of bone morphogenetic protein-2 gene polymorphisms with susceptibility to ossification of the posterior longitudinal ligament of the spine and its severity in Chinese patients.
246. Targeting of bone morphogenetic protein growth factor complexes to fibrillin.
247. GLI2-specific transcriptional activation of the bone morphogenetic protein/activin antagonist follistatin in human epidermal cells.
248. Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LbetaT2 gonadotrophs.
249. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
250. Oocyte-specific overexpression of mouse bone morphogenetic protein-15 leads to accelerated folliculogenesis and an early onset of acyclicity in transgenic mice.
251. Notch and bone morphogenetic protein differentially act on dermomyotome cells to generate endothelium, smooth, and striated muscle.
252. Prenatal lung epithelial cell-specific abrogation of Alk3-bone morphogenetic protein signaling causes neonatal respiratory distress by disrupting distal airway formation.
253. Endovascular treatment of experimental aneurysms with use of fibroblast transfected with replication-deficient adenovirus containing bone morphogenetic protein-13 gene.
254. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells.
255. A human bone morphogenetic protein antagonist is down-regulated in renal cancer.
256. Phosphorylation of bone morphogenetic protein-15 and growth and differentiation factor-9 plays a critical role in determining agonistic or antagonistic functions.
257. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis.
258. Constitutively active Akt induces ectodermal defects and impaired bone morphogenetic protein signaling.
259. Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors.
260. Elevated extracellular matrix production and degradation upon bone morphogenetic protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodeling.
261. Bone morphogenetic protein 4 modulates c-Kit expression and differentiation potential in murine embryonic aorta-gonad-mesonephros haematopoiesis in vitro.
262. A rapid and sensitive bioassay to measure bone morphogenetic protein activity.
263. Bone morphogenetic protein signaling and olig1/2 interact to regulate the differentiation and maturation of adult oligodendrocyte precursor cells.
264. Lead induces chondrogenesis and alters transforming growth factor-beta and bone morphogenetic protein signaling in mesenchymal cell populations.
265. A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN.
266. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft).
267. Differences in matrix accumulation and hypertrophy in superficial and deep zone chondrocytes are controlled by bone morphogenetic protein.
268. Role of RGM coreceptors in bone morphogenetic protein signaling.
269. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance.
270. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor.
271. The bone morphogenetic protein 1/Tolloid-like metalloproteinases.
272. Bone morphogenetic protein rescues the lack of secondary cartilage in Runx2-deficient mice.
273. Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling.
274. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor.
275. Potentiation of astrogliogenesis by STAT3-mediated activation of bone morphogenetic protein-Smad signaling in neural stem cells.
276. Cyclooxygenase-2 inhibitor reduces simvastatin-induced bone morphogenetic protein-2 and bone formation in vivo.
277. Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development.
278. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2.
279. TNF-alpha represses transcription of human Bone Morphogenetic Protein-4 in lung epithelial cells.
280. Antagonism between Notch and bone morphogenetic protein receptor signaling regulates neurogenesis in the cerebellar rhombic lip.
281. Modulation of Bone Morphogenetic Protein (BMP) 2 gene expression by Sp1 transcription factors.
282. The role of bone morphogenetic protein 4 in inner ear development and function.
283. Herpes simplex virus type-1 latency-associated transcript-induced immunoreactivity of substance P in trigeminal neurons is reversed by bone morphogenetic protein-7.
284. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2.
285. Accelerators of osteogenesis by recombinant human bone morphogenetic protein-2.
286. Bone morphogenetic protein signaling regulates the size of hair follicles and modulates the expression of cell cycle-associated genes.
287. Bone morphogenetic protein-induced MSX1 and MSX2 inhibit myocardin-dependent smooth muscle gene transcription.
288. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation.
289. Segmental bone regeneration using a load-bearing biodegradable carrier of bone morphogenetic protein-2.
290. Osteogenic differentiation of mouse adipose-derived adult stromal cells requires retinoic acid and bone morphogenetic protein receptor type IB signaling.
291. Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices.
292. Simultaneous gene transfer of bone morphogenetic protein (BMP) -2 and BMP-7 by in vivo electroporation induces rapid bone formation and BMP-4 expression.
293. The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling.
294. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis.
295. Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells.
296. Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth.
297. Bone apposition to titanium implants biocoated with recombinant human bone morphogenetic protein-2 (rhBMP-2). A pilot study in dogs.
298. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein.
299. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro.
300. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype.
301. Bone morphogenetic protein 4: potential regulator of shear stress-induced graft neointimal atrophy.
302. Bone morphogenetic protein signaling modulates myocardin transactivation of cardiac genes.
303. Expression of bone morphogenetic protein 2 in normal spontaneous labor at term, preterm labor, and preterm premature rupture of membranes.
304. NRAGE mediates p38 activation and neural progenitor apoptosis via the bone morphogenetic protein signaling cascade.
305. Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
306. GDF11 forms a bone morphogenetic protein 1-activated latent complex that can modulate nerve growth factor-induced differentiation of PC12 cells.
307. Stimulatory effects of distinct members of the bone morphogenetic protein family on ligament fibroblasts.
308. High-level activation of cyclic AMP signaling attenuates bone morphogenetic protein 2-induced sympathoadrenal lineage development and promotes melanogenesis in neural crest cultures.
309. Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling.
310. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis.
311. Localization and action of Dragon (repulsive guidance molecule b), a novel bone morphogenetic protein coreceptor, throughout the reproductive axis.
312. Bone morphogenetic protein 9 induces the transcriptome of basal forebrain cholinergic neurons.
313. Integrin-linked kinase mediates bone morphogenetic protein 7-dependent renal epithelial cell morphogenesis.
314. Induction of ectopic olfactory structures and bone morphogenetic protein inhibition by Rossy, a group XII secreted phospholipase A2.
315. The nucleocytoplasmic shuttling protein CIZ reduces adult bone mass by inhibiting bone morphogenetic protein-induced bone formation.
316. crossveinless defines a new family of Twisted-gastrulation-like modulators of bone morphogenetic protein signalling.
317. Induction of chondro-, osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: effect of cofactors on differentiating lineages.
318. Bone morphogenetic protein (BMP) signaling controls hair pigmentation by means of cross-talk with the melanocortin receptor-1 pathway.
319. B-cell translocation gene 2 (Btg2) regulates vertebral patterning by modulating bone morphogenetic protein/smad signaling.
320. Cleavages within the prodomain direct intracellular trafficking and degradation of mature bone morphogenetic protein-4.
321. Bone morphogenetic protein signaling regulates postnatal hair follicle differentiation and cycling.
322. Immunohistochemical localization of the bone morphogenetic protein receptors in the porcine ovary.
323. Bone morphogenetic protein 2-induced osteoblast differentiation requires Smad-mediated down-regulation of Cdk6.
324. Ca2+ channel regulation by transforming growth factor-beta 1 and bone morphogenetic protein-2 in developing mice myotubes.
325. The bone morphogenetic protein type Ib receptor is a major mediator of glial differentiation and cell survival in adult hippocampal progenitor cell culture.
326. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene.
327. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein.
328. Cysteine repeat domains and adjacent sequences determine distinct bone morphogenetic protein modulatory activities of the Drosophila Sog protein.
329. Porous bone morphogenetic protein-2 microspheres: polymer binding and in vitro release.
330. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription.
331. Smad-dependent recruitment of a histone deacetylase/Sin3A complex modulates the bone morphogenetic protein-dependent transcriptional repressor activity of Nkx3.2.
332. Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2.
333. GATA- and Smad1-dependent enhancers in the Smad7 gene differentially interpret bone morphogenetic protein concentrations.
334. BMPER, a novel endothelial cell precursor-derived protein, antagonizes bone morphogenetic protein signaling and endothelial cell differentiation.
335. Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation.
336. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads.
337. Bone morphogenetic protein 4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression.
338. Nuclear factor YY1 inhibits transforming growth factor beta- and bone morphogenetic protein-induced cell differentiation.
339. Use of Bmp1/Tll1 doubly homozygous null mice and proteomics to identify and validate in vivo substrates of bone morphogenetic protein 1/tolloid-like metalloproteinases.
340. The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle.
341. Gene therapy of bone morphogenetic protein for periodontal tissue engineering.
342. Retinoic acid repression of bone morphogenetic protein 4 in inner ear development.
343. Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis.
344. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk.
345. Bone morphogenetic protein and retinoic acid signaling cooperate to induce osteoblast differentiation of preadipocytes.
346. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4.
347. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension.
348. Bone morphogenetic protein-4-induced activation of Xretpos is mediated by Smads and Olf-1/EBF associated zinc finger (OAZ).
349. Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation.
350. A negative feedback system between oocyte bone morphogenetic protein 15 and granulosa cell kit ligand: its role in regulating granulosa cell mitosis.
351. YY1 activates Msx2 gene independent of bone morphogenetic protein signaling.
352. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3.
353. Bone morphogenetic protein-2 (BMP-2) transactivates Dlx3 through Smad1 and Smad4: alternative mode for Dlx3 induction in mouse keratinocytes.
354. Bone morphogenetic protein 4 in the extraembryonic mesoderm is required for allantois development and the localization and survival of primordial germ cells in the mouse.
355. Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons.
356. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding.
357. Bone morphogenetic protein-2 (BMP-2) and transforming growth factor-beta1 (TGF-beta1) alter connexin 43 phosphorylation in MC3T3-E1 Cells.
358. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads.
359. Mutation in bone morphogenetic protein receptor-IB is associated with increased ovulation rate in Booroola Mérino ewes.
360. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions.
361. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12.
362. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.
363. Estrogen opposes the apoptotic effects of bone morphogenetic protein 7 on tissue remodeling.
364. Bone morphogenetic protein 4 regulates the budding site and elongation of the mouse ureter.
365. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors.
366. Characterization of a bone morphogenetic protein-responsive Smad-binding element.
367. Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation.
368. Protein kinase signalling pathways involved in the up-regulation of the rat alpha1(I) collagen gene by transforming growth factor beta1 and bone morphogenetic protein 2 in osteoblastic cells.
369. A functional bone morphogenetic protein system in the ovary.
370. Genetic analysis of the bone morphogenetic protein-related gene, gbb, identifies multiple requirements during Drosophila development.
371. Cloning and functional characterization of the 5'-flanking region of the human bone morphogenetic protein-2 gene.
372. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases.
373. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.
374. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo.
375. Differential roles for bone morphogenetic protein (BMP) receptor type IB and IA in differentiation and specification of mesenchymal precursor cells to osteoblast and adipocyte lineages.
376. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.
377. Bone morphogenetic protein signaling is required for maintenance of differentiated phenotype, control of proliferation, and hypertrophy in chondrocytes.
378. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2.
379. Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen.
380. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage.
381. Bone morphogenetic protein receptors and activin receptors are highly expressed in ossified ligament tissues of patients with ossification of the posterior longitudinal ligament.
382. Overexpression of bone morphogenetic protein-6 (BMP-6) in the epidermis of transgenic mice: inhibition or stimulation of proliferation depending on the pattern of transgene expression and formation of psoriatic lesions.
383. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7).
384. Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
385. Competition between noggin and bone morphogenetic protein 4 activities may regulate dorsalization during Xenopus development.
386. Independent changes in type I and type II receptors for transforming growth factor beta induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype.
387. Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development.
388. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage.
389. A truncated bone morphogenetic protein 4 receptor alters the fate of ventral mesoderm to dorsal mesoderm: roles of animal pole tissue in the development of ventral mesoderm.
390. A truncated bone morphogenetic protein receptor affects dorsal-ventral patterning in the early Xenopus embryo.
391. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects.
392. Bone morphogenetic protein 2 transiently enhances expression of a gene, Id (inhibitor of differentiation), encoding a helix-loop-helix molecule in osteoblast-like cells.
393. Biochemical properties of amphibian bone morphogenetic protein-4 expressed in CHO cells.
394. Bone morphogenetic protein expression in human atherosclerotic lesions.
395. Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein, DVR-6 (bone morphogenetic protein-6).
396. Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression.
397. Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: potentiation and binding to type IV collagen.
398. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro.
399. Identification and characterization of cellular binding proteins (receptors) for recombinant human bone morphogenetic protein 2B, an initiator of bone differentiation cascade.
400. Bone morphogenetic protein 1 is homologous in part with calcium-dependent serine proteinase.
401. Recombinant human bone morphogenetic protein induces bone formation.
402. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography.
403. The reaction of the dura to bone morphogenetic protein (BMP) in repair of skull defects.
404. Solubilized and insolubilized bone morphogenetic protein.